英派药业-B（07630）8月11日发布盈利预告称，预计截至2026年6月30日止六个月的收入约94.7百万元至约1.16亿元，较2025年同期的25.2百万元增长约276%至359%。同期公司预计录得期内亏损约81.7百万元至99.9百万元，较上一年度同期的128.7百万元减少约37%至22%。\n\n公司表示，收入大幅增长主要受三方面驱动：一是PARP抑制剂塞纳帕利于2026年初纳入国家医保药品目录后，商业化进程加速；二是与Eikon Therapeutics, Inc.签订合作协议后，IMP1734进入II期临床试验带来的里程碑付款；三是终止普通股贖回负債后产生的利息减少，从而收窄亏损。\n\n英派药业-B预计将在2026年8月公布中期业绩。公司提醒投资者在买卖公司证券时保持审慎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.